FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
SAN DIEGO, Sept. 11, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at two upcoming investor conferences in New York City, including:
Cantor Fitzgerald Global Healthcare Conference
Date: Monday, September 25, 2017
Time: 9:45 a.m. ET
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Date: Wednesday, September 27, 2017
Time: 1:30 p.m. ET
Live webcasts will be available at http://ir.retrophin.com/events, and archived replays will be accessible for up to 30 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Thiola®, Cholbam® and Chenodal®. retrophin.com
Contact: Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 [email protected]
